title: Current achievements and future perspectives of metronomic chemotherapy.
abstract: In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.
authors.affiliation: Clinical and Molecular Medicine Department, Sapienza University, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. adriana.romiti@uniroma1.it.
authors.forename: Adriana
authors.initials: A
authors.lastname: Romiti
authors.affiliation: Clinical and Molecular Medicine Department, Sapienza University, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Falcone
authors.affiliation: Clinical and Molecular Medicine Department, Sapienza University, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Roberto
authors.affiliation: Clinical and Molecular Medicine Department, Sapienza University, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Marchetti
mesh_terms: D059250:Administration, Metronomic; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000073496:Frailty; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents
keywords: Elderly; Immunotherapy; Low-dose chemotherapy; Metronomic chemotherapy; Predictive biomarkers